In order to resolve current controversies on isosorbide dinitrate (ISDN), we employed a particularly sensitive testing protocol to evaluate effects of sublingual ISDN and nitroglycerin on the exercise capacity of patients with angina. Ten minutes after ISDN 21 of 23 patients exercised longer (average 2.7 minutes, P < 0.001) than after placebo. Benefit was evident in only a minority of patients tested one hour and in none tested two hours after either ISDN or nitroglycerin. A given amount of exercise resulted in lower mean blood pressure (average 13 mm Hg, P < 0.001), higher heart rate (average 10 beats/min, P < 0.001), and shorter ejection time (average 0.04 second, P < 0.001) after ISDN. Similar changes were seen after nitroglycerin. The product of blood pressure, heart rate, and ejection time, an index of myocardial 02 
Seeking to resolve this controversy, we studied the influence of sublingually administered ISDN on the exercise performance of patients with angina pectoris. Our approach differed fundamentally from methods of previous investigators as follows: (1) We employed a particularly sensitive exercise protocol which we have shown to be reliable in identifying alterations in the exercise capacity of patients with angina produced by various interventions.7 (2) We chose drug dosages for each subject on the basis of physiologic response in the resting state. (3) We obtained direct, continuous measurement of circulatory parameters closely related to myocardial oxygen demand, thus permitting a comparison of clinical performance with those physiologic 629 alterations likely to influence the precipitation of angina. Using these methods, we evaluated the time course of both symptomatic and circulatory changes associated with the administration of ISDN. Furthermore, to determine if this drug is truly "long-acting," we compared the duration of action of ISDN with that of nitroglycerin. We also assessed the acute effects of nitrates on exercise performance before and after long-term ISDN treatment to determine if chronic exposure to this drug impaired patient responsiveness to nitrates.
Methods Twenty-three patients exercised until the onset of angina before and at varying lengths of time after treatment with placebo, ISDN, or nitroglycerin. Patients ranged in age from 34 to 67 years (median 52 years). Although ten had either type II or type IV hyperlipoproteinemia, none had overt diabetes, hypertension, clinically apparent disease of cerebral or peripheral arteries, or any significant complicating medical condition. Each patient had had stable, typical angina pectoris for at least six months prior to study. Twenty-two had evidence of one or more acute myocardial infarctions, and all of the 17 individuals who had coronary arteriography were found to have greater than 75% narrowing of one or more coronary arteries. Of the 12 patients who had left ventriculography, nine had areas of akinesia, and four had chamber enlargement. Ten patients were receiving digitalis, but none was in overt congestive heart failure.
Patients participating in this study were chosen from those individuals admitted to the National Heart and Lung Institute for evaluation and therapy of angina. Despite evidence of severe coronary occlusive disease, many of these individuals led moderately active lives, and some worked full-time. Elderly patients and patients with associated diseases were excluded in the course of selecting candidates for admission to the National Heart and Lung Institute. However, we do not feel that this selection process was likely to influence our results or conclusions.
Patients exercised in the upright position on a Godart bicycle ergometer until the onset of angina or until the development of leg fatigue sufficient to preclude further exercise. Work load was increased 20 w every three minutes; load at outset was chosen individually so that each patient developed angina from three to six minutes after starting. The appropriateness of the work levels chosen and the consistency of patient performance were confirmed in each instance by preliminary trials on the ergometer in the absence of any drug on at least two different days.
During the definitive study intra-arterial pressure was measured through a Coumand needle in the brachial artery or through a no. 5 Elecath with end and side holes positioned so that its tip lay in the descending thoracic aorta. The electrocardiogram was also recorded continuously, using apical-manubrial or apical-subscapular bipolar chest leads. At The The decrease in blood pressure during exercise seen after ISDN was accompanied by a consistent rise in heart rate, averaging 10 beats per minute, and a consistent decrease in ejection time, averaging 0.04 second or 17% ( fig. 7) . Examination of the circulatory responses in the one patient (designated by asterisks in fig. 7 ) to experience a marked deterioration of exercise capacity following ISDN revealed a slight rise in blood pressure and a very marked rise in heart rate during exercise after ISDN. The additional oxygen cost of the excessively rapid heart rate and the unusual rise in blood pressure during exercise (despite a fall in blood pressure at rest) probably explains why angina was precipitated much earlier in this one individual following ISDN.
A decrease in blood pressure and ejection time and increase in heart rate similar to that exercise capacity initially. This increment tended to disappear at approximately the same rate for both drugs. Because of the roughly exponential character of this disappearance, a linearizing logarithmic transformation was performed on the increments. Regression lines fitted to the transformed data (bottom)
were indistinguishable for the two drugs-the halftimes for the increments in exercise capacity associated with either ISDN or nitroglycerin (TNG) were virtually identical. Comparison of mean blood pressure, heart rate, and ejection time during exercise after placebo and after nitroglycerin (TNG), analogous to material presented for ISDN in figure 7.
following ISDN was observed during exercise after nitroglycerin ( fig. 8 ).
Since blood pressure and heart rate are both important determinants of myocardial oxygen requirements, the product of these two quantities is often used as an index of myocardial oxygen consumption.9 PressureCirculation, Volume XLIII, May 1971 rate product was significantly higher at the onset of angina after treatment with either ISDN or nitroglycerin ( fig. 9, left) . These results might suggest that the two drugs increased myocardial oxygen delivery, possibly through a direct effect on coronary circulation. However, since the time during Pressure-rate product and triple product (blood pressure X heart rate X ejection time) In addition to blood pressure, heart rate, and ejection time, ventricular size is also known to exert an influence on myocardial oxygen requirements.", 12 Nitroglycerin has been shown to decrease ventricular dimensions during supine exercise.13 In our subjects measurement of maximum width of the cardiac silhouette during equal amounts of upright subanginal exercise ( fig. 10 ) demonstrated a significant decrease in over-all cardiac size when either ISDN (average 2.3%, P <0.025) or nitroglycerin (average 2.1%, P <0.05) was compared with placebo. Similarly, decreases occurred while sitting at rest (average 3.8% after ISDN and 3.6% after nitroglycerin, P < 0.001).
Results After Chronic Treatment with ISDN
The acute effects of ISDN on exercise performance in ten patients regularly receiving sublingual ISDN (5 to 10 mg qid) were compared with the effects achieved when the patients had been on placebo. Six individuals were given ISDN for ten days prior to study, while the other four remained on treatment for one to seven months. In six randomly selected patients the course of placebo preceded ISDN; in four, a one-to two-week course of placebo followed ISDN. The rate of nitroglycerin consumption in any patient during therapy with either ISDN or placebo fluctuated widely; there was no consistent difference between the two treatment periods. Exercise testing was initiated at least two hours after the last regular dose of either ISDN or placebo. No significant difference was observed in baseline exercise capacity after chronic treatment with ISDN. Blood pressure and heart rate responses and pressure-rate product at angina were also the same after chronic ISDN and after placebo. Moreover, the chronic administration of ISDN did not alter the usual response to the drug when administered acutely. Ten minutes after the sublingual administration of ISDN, the same increase in exercise capacity, the same changes in blood pressure and heart rate, and the same pressure-rate product at angina occurred whether the patient had been chronically taking ISDN Figure 11 Example illustrating the action of ISDN. The triple product (systolic blood pressure X heart rate X ejection time) on the vertical axis is represented as a function of the duration of exercise, shown on the horizontal time scale. Levels of work load are indicated by the shaded areas, while dashed vertical lines denote times of work load increment. Asterisks represent the onset of angina. The two solid lines show the changes in triple product during the course of exercise preceded by no treatment (slightly higher asterisk) and during exercise preceded by placebo (slightly lower asterisk). As illustrated by the dashed line, a given amount of exercise after ISDN resulted in a lower triple product. The patient was able to exercise for a considerably longer period and could perform work against a greater load prior to the onset of angina. Angina eventually did occur, however, when the paticnt reached the same limiting level of triple product associated with the onset of angina in the absence of ISDN. figure 11 , a plot of the triple product of systolic blood pressure x heart rate X ejection time during the course of exercise. Following ISDN the triple product rises more slowly, but angina occurs when the triple product reaches the same critical level. Thus, ISDN appears to enhance exercise capacity by lowering triple product (and, presumably, myocardial oxygen demand) at any given level of exercise, but ISDN treatment does not permit the patient to exceed that value of the triple product previously associated with the onset of angina.
Circulation, Volume XLIII, May 1971 Such an analysis may be overly simplified since the triple product does not take into account potentially important influences affecting myocardial oxygen requirements, such as the inotropic state of the heart or left ventricular size, which may change significantly after ISDN or nitroglycerin. These agents might also act to change myocardial oxygen delivery: blood flow to ischemic regions of the myocardium might either be augmented as a result of coronary vasodilation or reduced secondary to the decrease in systemic (and thus coronary) perfusion pressure. Should ISDN or nitroglycerin produce major change in myocardial oxygen delivery or utilization by any of these mechanisms, a corresponding increase or decrease in the triple product at the onset of angina would logically be anticipated. The complete absence of change in the triple product at angina following ISDN or nitroglycerin suggests that alterations in these factors are not sufficiently important to change myocardial oxygen requirements significantly and that the improvement in exercise capacity caused by these drugs is primarily related to alterations in myocardial oxygen demands due to changes in blood pressure, heart rate, and ejection time. The possibility remains, however, that ISDN and nitroglycerin do cause significant changes in ventricular size, myocardial contractility, and myocardial perfusion and that the constancy of the triple product at angina occurs only because these changes fortuitously cancel out.
